run_metadata: 45040
This data as json
| rowid | run.accession | experiment.accession | sample.accession | study.accession | bioproject | study.title | study.alias | study.type | study.abstract | study.attributes | study.PMIDs | sample.description | sample.title | sample.alias | sample.centername | sample.attributes | GEOsample.title | GEOsample.dataprocessing | GEOsample.source | GEOsample.treatmentprotocol | GEOsample.extractprotocol | GEOsample.growthprotocol | GEOsample.characteristics | GEOsample.accession | experiment.title | experiment.alias | experiment.library_name | experiment.design_description | experiment.library_construction_protocol | experiment.attributes | experiment.library_strategy | experiment.library_source | experiment.library_selection | experiment.library_layout | experiment.platform | experiment.instrument_model | experiment.spot_descriptor | experiment.study_ref | run.title | run.attributes | run.filename | run.semantic_name | run.total_bases | run.total_spots | run.alias | run.read_lengths | run.base_counts | run.r1_length | run.r2_length | run.r3_length | run.r4_length | run.Acount | run.Ccount | run.Gcount | run.Tcount | run.Ncount | run.experiment | run.pool_member | submission.accession | submission.srasource | submission.bioprojectsource | seqdetective.n_mates | seqdetective.mapping_rate.mate1 | seqdetective.mapping_rate.mate2 | seqdetective.nofeature_rate.mate1 | seqdetective.nofeature_rate.mate2 | seqdetective.sparsity.mate1 | seqdetective.sparsity.mate2 | seqdetective.pos_strand_rate.mate1 | seqdetective.pos_strand_rate.mate2 | seqdetective.readlen.mate1 | seqdetective.readlen.mate2 | seqdetective.judgement.mate1 | seqdetective.judgement.mate2 | seqdetective.judgement.reason | platform_family | instrument_generation | read_bias | selection_class | prep_kit | sc_or_bulk | tech_class | technology | tech_variant | submission.bioprojectsource.country | earliest_date | devstage_curation | devstage_curation_coarse | tissue_curation | tissue_curation_coarse |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45040 | SRR6494610 | SRX3583936 | SRS2852962 | SRP130950 | PRJNA428951 | Cell of origin dictates aggression and stem cell activity in acute lymphoblastic leukemia | GSE108855 | Transcriptome Analysis | Subclassification of lymphoid neoplasms is often based on the presumed cell of origin based on T and B progenitor gene expression and the effect of cell lineage on influencing functional characteristics such as aggression and self renewal capacity is largely unknown accounted for in part by lack of experimental models to address these questions. Here we have used transgenic zebrafish to create the first models of Myc induced B ALL and mixed phenotypic B/T ALL opening new avenues for studying the these leukemias in the zebrafish. Our work has utilized syngeneic strain zebrafish limiting dilution cell transplantation and the widely reported rag2 Myc transgenic model to provide new understanding of how strain differences can underlie leukemia onset in the zebrafish model. Even more importantly our work now for the first time has allowed assessment of cell lineage on dictating aggression and leukemia stem cell frequency independent of the underlying oncogenic driver. In total our work uncoveres that T ALLs are more aggressive and have higher numbers of leukemia stem cells when compared with B ALL and mixed phenotypic ALL. Furthermore analysis of our biphenotypic B/T ALL suggests that B cell pathways lock cells in less aggressive and lower stem cell fates and are dominant in regulating these processes when T cell pathways are co regulated within ALL cells. Overall design: The goal of our study is to determine the transcriptional profiles of high and low self renewing capacity tumors. 20 samples total: 11 unique samples 9 samples with biological replicates 6 high self renewing tumors >1% cells could initiate leukemia and 5 low self renewing tumors <1% of cells could initiate leukemia. | pubmed:29749398 | 9.2A | GSM2915052 | tissue:Leukemia cells|replicate number:1|self renewal capacity:low|background strain:CG1|cell type:blood | 9.2A | Demultiplexed reads were aligned using STARDobin et al. 2013 to GRCz10. We used picard to filter out PCR duplicates and also removed reads aligning to rRNA intervals. We then assigned counts to each gene using featureCountsLiao Y Smyth GK and Shi W 2014. Genome build: GRCz10 Supplementary files format and content: count matrix provided as supplementary file | Leukemia cells | Leukemia cell pellets were mixed 350ul of QIAGEN RLT buffer containing 1% 2 mercaptoethanol followed by RNA isolation using the RNAeasy Mini kit QIAGEN. RNA samples were prepped and sequenced on the Illumina HiSeq 2000 platform as previously described in Tang et al. PMID 28878000. RNA from bulk tumors were reverse transcribed and sequenced on the Illumina HiSeq 2000 platform. | replicate number:1|self renewal capacity:low|background strain:CG1|cell type:blood | GSM2915052 | GSM2915052: 9.2A; Danio rerio; RNA Seq | GSM2915052 | 1 | Leukemia cell pellets were mixed 350ul of QIAGEN RLT buffer containing 1% 2 mercaptoethanol followed by RNA isolation using the RNAeasy Mini kit QIAGEN. RNA samples were prepped and sequenced on the Illumina HiSeq 2000 platform as previously described in Tang et al. PMID 28878000. RNA from bulk tumors were reverse transcribed and sequenced on the Illumina HiSeq 2000 platform. | GEO Accession:GSM2915052 | RNA-Seq | TRANSCRIPTOMIC | cDNA | PAIRED | ILLUMINA | Illumina HiSeq 2000 | SRP130950 | 9.2A_R1.fastq.gz 9.2A_R2.fastq.gz | fastq fastq | 4360921770.0 | 42754135.0 | GSM2915052 r1 | 0:51 1:51 | A:1079666608;C:1084041944;G:1104190687;T:1087055139;N:5967392 | 51 | 51 | 1079666608 | 1084041944 | 1104190687 | 1087055139 | 5967392 | SRX3583936 | SRS2852962 | SRA649887 | GEO | Pathology, Massachusetts General Hospital | 2 | 0.93401 | 0.93834 | 0.24172 | 0.23839 | 0.79543 | 0.79853 | 0.54668 | 0.56646 | 51 | 51 | B | B | biological fallback assumption | illumina | hiseq_era | unknown | cdna_unspecified | unknown | bulk | bulk | bulk | United States | 2018-01-08 | Undetermined | Undetermined | Cancer or Tumor | Cancer or Tumor |